Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.88 |
| ▸ | PGR | P06401 | 8/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.88 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.88 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.88 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.88 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.88 |
| ▸ | IL5 | P05113 | 1/20 | 0.88 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.88 |
| ▸ | AR | P10275 | 1/20 | 0.88 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.88 |
| ▸ | MMP9 | P14780 | 1/20 | 0.88 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.88 |
| ▸ | THPO | P40225 | 1/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.88 |
| ▸ | BLM | P54132 | 1/20 | 0.88 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24622229 | 1.00 | NR3C1 (0.88) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| SCHEMBL13652071 | 1.00 | NR3C1 (0.88) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL13695912 | 0.94 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL12396756 | 0.94 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL13928654 | 0.94 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL14452945 | 0.94 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL1130417 | 0.94 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL13871728 | 0.94 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL21570019 | 0.94 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL8056801 | 0.94 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 465 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144040-A1 | COMPOSITE PARTICLE FORMULATIONS AND APPLICATIONS THEREOF | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2025-05-08 | — | — | US | claimed |
| US-20240408186-A1 | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) WITH TOLERIZING NANOPARTICLES | COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC. | 2024-12-12 | — | — | US | claimed |
| EP-4419149-A1 | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) WITH TOLERIZING NANOPARTICLES | Cour Pharmaceuticals Development Company Inc. (US) | 2024-08-28 | — | — | EP | claimed |
| US-20230398131-A1 | PHARMACEUTICAL SPRAY COMPOSITION COMPRISING A VITAMIN D ANALOGUE AND CORTICOSTEROID | LEO PHARMA AS (DK) | 2023-12-14 | — | — | US | claimed |
| EP-3843705-B1 | PREPARATION OF NANOSUSPENSION COMPRISING NANOCRYSTALS OF ACTIVE PHARMACEUTICAL INGREDIENTS WITH LITTLE OR NO STABILIZING AGENTS | CENTRE NAT RECH SCIENT (FR) | 2023-11-29 | — | — | EP | claimed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| US-11786574-B2 | Treatment of rhinosinusitis with p-glycoprotein inhibitors | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2023-10-17 | — | — | US | claimed |
| US-20230310597-A1 | Combination Of The Application Of Antibodies For Immunostimulation Together With Glucocorticoids | LINDHOFER, HORST (DE) | 2023-10-05 | — | — | US | claimed |
| WO-2023141278-A2 | COMPOSITE PARTICLE FORMULATIONS AND APPLICATIONS THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-07-27 | — | — | WO | claimed |
| WO-2023070104-A1 | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) WITH TOLERIZING NANOPARTICLES | COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC. (US) | 2023-04-27 | — | — | WO | claimed |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | claimed |
| EP-4447988-B1 | COMPOSITIONS FOR TREATING AUTOIMMUNE ARTHRITIS | DEVINTEC SAGL (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-3937966-B1 | COMPOSITIONS AND METHODS FOR PROTECTING TYPE 2 ALVEOLAR EPITHELIAL CELLS (AEC2) | REIN THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735023-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | Piton Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12617858-B2 | Anti-Müllerian hormone receptor 2 antibodies and methods of use | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-05-05 | — | — | US | disclosed |
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220024962-A1 | SOLID FORMS OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID | H. LUNDBECK A/S (DK) | 2022-01-27 | — | — | US | disclosed |
| US-20110223203-A1 | NANOCLUSTER COMPOSITIONS AND METHODS | UNIVERSITY OF KANSAS | 2011-09-15 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398131-A1 | PHARMACEUTICAL SPRAY COMPOSITION COMPRISING A VITAMIN D ANALOGUE AND CORTICOSTEROID | CYP24A1, CYP2R1, VDR | NR3C1 34/4885PGR 395/4885CYP3A4 227/4885 |
| US-20220024962-A1 | SOLID FORMS OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID | PARK7, PAH, HTR3D | NR3C1 1601/4885PGR 697/4885CYP3A4 49/4885 |
| US-11247989-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, CREBBP | NR3C1 90/4885PGR 2107/4885CYP3A4 4474/4885 |
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | SDHA, PAH, PIGS | NR3C1 3930/4885PGR 1393/4885CYP3A4 130/4885 |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | NR3C1 429/4885PGR 419/4885CYP3A4 12/4885 |
| US-20250144040-A1 | COMPOSITE PARTICLE FORMULATIONS AND APPLICATIONS THEREOF | ANAPC7, SARS1, CORO1C | NR3C1 1700/4885PGR 932/4885CYP3A4 1054/4885 |
| US-12617858-B2 | Anti-Müllerian hormone receptor 2 antibodies and methods of use | TGFBR2, TNFSF11, TNFRSF9 | NR3C1 2233/4885PGR 48/4885CYP3A4 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.